ArticleCurrent oncology (Toronto, Ont.)2008
Cetuximab treatment in a patient with metastatic colorectal cancer and psoriasis.
Article in Current oncology (Toronto, Ont.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01006096 (Phase II Randomized, Double-blind, Placebo-controlled, Two-arm Study to Evaluate the Safety and Efficacy of Erlotinib in the Treatment of Moderate to Severe Psoriasis), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Randomized, Double-blind, Placebo-controlled, Two-arm Study to Evaluate the Safety and Efficacy of Erlotinib in the Treatment of Moderate to Severe Psoriasis
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Psoriasis in the Era of Targeted Cancer Therapeutics: A Systematic Review on De Novo and Pre-existing Psoriasis in Oncologic Patients Treated with Emerging Anti-neoplastic Agents.Dermatology and therapy · 2024Review
- Interleukin-17A and Keratinocytes in Psoriasis.International journal of molecular sciences · 2020Review
- The EGFR-ERK/JNK-CCL20 Pathway in Scratched Keratinocytes May Underpin Koebnerization in Psoriasis Patients.International journal of molecular sciences · 2020Article
- JNK1 Signaling Downstream of the EGFR Pathway Contributes to AldaraFrontiers in immunology · 2020Article
- Recent advances on the roles of epidermal growth factor receptor in psoriasis.American journal of translational research · 2019Review
- The Immunogenetics of Psoriasis and Implications for Drug Repositioning.International journal of molecular sciences · 2017Review
- A case of psoriasis pustolosa palmaris induced by cetuximab.BMJ case reports · 2016Article
- Cetuximab and panitumumab in a patient with colon cancer and concomitant chronic skin disease: a potential beneficial effect on psoriasis vulgaris.World journal of gastroenterology · 2015Article
- Involvement of TNF-α converting enzyme in the development of psoriasis-like lesions in a mouse model.PloS one · 2014Article
- Pharmacological control of receptor of advanced glycation end-products and its biological effects in psoriasis.International journal of biomedical science : IJBS · 2013Article
- Tyrosine kinases in inflammatory dermatologic disease.Journal of the American Academy of Dermatology · 2011Review
- Keratinocyte but not endothelial cell-specific overexpression of Tie2 leads to the development of psoriasis.The American journal of pathology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor, has activity against colorectal cancer. Treatment is associated with skin toxicity, and the safety of cetuximab in patients with psoriasis is unknown. We report the case of a male patient with stage iv colorectal cancer (crc) and a life-long history of extensive psoriasis. This patient experienced a durable remission of his crc and major improvement of his psoriasis during single-agent treatment with cetuximab. We conclude that, despite its known skin toxicity, cetuximab treatment can be offered to colorectal patients suffering from psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.